Home Ingredients Sukré® (Ultra-Pure Allulose)
Metabolic HealthWeight Management

Sukré® (Ultra-Pure Allulose)

Evidence Level
Moderate
1 Clinical Trial
3 Documented Benefits
3/5 Evidence Score

Sukré® (Compound Solutions) is an ultra-pure allulose (D-psicose) sweetener — a rare monosaccharide found naturally in trace amounts in figs, raisins, and maple syrup that provides 70% of sucrose's sweetness at 0.4 kcal/g (vs. 4 kcal/g for sucrose). Unlike other sugar alcohols and alternative sweeteners, allulose has FDA GRAS status, is excluded from total and added sugar counts on Nutrition Facts labels (FDA ruling), produces no glycemic or insulinemic response, and has demonstrated metabolic health benefits at higher intakes. Sukré® differentiates through purity and clean taste profile.

Studied Dose As sweetener: 5–15g/serving; metabolic health benefits: 7–15g/day allulose with meals; FDA acceptable daily intake not formally established but well-tolerated up to 54g/day in studies
Active Compound D-psicose (allulose) — Sukré® by Compound Solutions; ultra-pure allulose; FDA GRAS; excluded from sugar labeling per FDA guidance

Benefits

Sugar-free, zero-glycemic sweetening with calorie label exclusion

Sukré® provides sweetness at ~70% of sucrose intensity with only 0.4 kcal/g caloric contribution — and per FDA guidance, allulose can be excluded from total and added sugar labeling. This dual advantage (functional sweetness + label-friendly status) makes Sukré® uniquely valuable for clean-label products targeting sugar reduction without resorting to artificial sweeteners or high-intensity sweetener blends.

Supported by Trial 1

Blood glucose and insulin reduction

Multiple clinical RCTs confirm allulose reduces postprandial blood glucose and insulin response when consumed with carbohydrate meals — inhibiting intestinal alpha-glucosidase enzymes (similar to acarbose, a diabetes medication) to slow glucose absorption. This glucose-lowering mechanism extends allulose beyond sweetening into active metabolic health ingredient territory.

Supported by Trial 1

Body fat reduction and anti-obesity effects

A meta-analysis of RCTs confirmed allulose supplementation (7–15g/day) significantly reduced body weight, BMI, waist circumference, and body fat percentage vs. control — effects attributed to alpha-glucosidase inhibition reducing carbohydrate absorption, improved fat oxidation signaling, and gut microbiome modulation including increased Akkermansia muciniphila abundance.

Supported by Trial 1

Mechanism of action

1

Alpha-glucosidase inhibition and Akkermansia stimulation

Allulose competitively inhibits intestinal brush border alpha-glucosidases (maltase, sucrase) — enzymes that break down complex carbohydrates into glucose for absorption. This mechanism reduces glucose absorption rate and postprandial glycemia, functioning similarly to the pharmaceutical alpha-glucosidase inhibitor acarbose but with substantially better GI tolerance. Unabsorbed allulose reaching the colon selectively promotes Akkermansia muciniphila growth — a keystone mucus-layer bacterium associated with improved metabolic health, insulin sensitivity, and reduced gut permeability.

Clinical trials

1
Allulose and Postprandial Glycemia — Meta-Analysis of RCTs
PubMed

Meta-analysis of 9 randomized controlled trials examining allulose effects on postprandial blood glucose, insulin, body composition, and metabolic markers.

Adults across 9 RCTs including subjects with and without metabolic syndrome.

Allulose significantly reduced postprandial blood glucose (−0.44 mmol/L), insulin area under the curve, body weight (−0.58 kg), and body fat vs. control. Alpha-glucosidase inhibitory mechanism confirmed. Well-tolerated up to 54g/day. Supports allulose as both a functional sweetener and metabolic health ingredient.

Side effects and drug interactions

Common Potential side effects

GI distress (bloating, diarrhea) at high single doses (>25g) — stay within 5–15g per serving
FDA GRAS status; excellent long-term safety data
May cause loose stools if consumed with other polyols (sorbitol, xylitol) — additive osmotic effect

Important Drug interactions

Diabetes medications — additive glucose-lowering effects at therapeutic doses; monitor blood glucose
No significant pharmacokinetic drug interactions at sweetener use levels

More Metabolic Health Ingredients

Cardiovascular
Niacin
Niacin (vitamin B3) is an essential water-soluble vitamin central to energy metabolism, DN…
Muscle & Recovery
Magnesium
Magnesium is the fourth most abundant mineral in the body and a cofactor for over 300 enzy…
Cardiovascular
Pycnogenol® (French Maritime Pine Bark)
Pycnogenol® (Horphag Research) is a standardized extract from the bark of French maritime…
Metabolic Health
Psyllium Husk (Plantago ovata)
Psyllium husk is the soluble fiber derived from the seed husks of Plantago ovata — the mos…

Explore Other Ingredients

Muscle & Recovery
L-Glutamine
L-glutamine is the most abundant amino acid in the body and the primary metabolic fuel for…
Antioxidant
Chlorella
Chlorella is a single-celled freshwater green algae rich in chlorophyll, complete protein…
Metabolic Health
Inulin
Inulin is a soluble prebiotic fiber found naturally in chicory root, agave, and many veget…

Frequently asked questions about Sukré® (Ultra-Pure Allulose)

What is Sukré?

Sukré® (Compound Solutions) is an ultra-pure allulose (D-psicose) sweetener — a rare monosaccharide found naturally in trace amounts in figs, raisins, and maple syrup that provides 70% of sucrose's sweetness at 0.4 kcal/g (vs. 4 kcal/g for sucrose).

What is Sukré used for?

Sukré is researched primarily for Metabolic Health and Weight Management. Sukré® provides sweetness at ~70% of sucrose intensity with only 0.4 kcal/g caloric contribution — and per FDA guidance, allulose can be excluded from total and added sugar labeling.

What is the recommended dosage of Sukré?

The clinically studied dose is As sweetener: 5–15g/serving; metabolic health benefits: 7–15g/day allulose with meals; FDA acceptable daily intake not formally established but well-tolerated up to 54g/day in studies Always follow the product label and check with a healthcare provider for personal advice.

Is Sukré safe, and does it have side effects?

For most healthy adults, Sukré is well tolerated at studied doses. Reported effects can include: GI distress (bloating, diarrhea) at high single doses (>25g) — stay within 5–15g per serving FDA GRAS status; excellent long-term safety data It may also interact with some medications. Sukré is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Sukré interact with any medications?

Possible interactions include: Diabetes medications — additive glucose-lowering effects at therapeutic doses; monitor blood glucose No significant pharmacokinetic drug interactions at sweetener use levels If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Sukré?

NutraSmarts rates the evidence for Sukré as Moderate (3 out of 5). It is backed by 1 clinical trial and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Tani Y, Tokuda M, Nishimoto N, Yokoi H, Izumori K Allulose for the attenuation of postprandial blood glucose levels in healthy humans: A systematic review and meta-analysis. PLoS One. 2023;18(4):e0281150. doi: 10.1371/journal.pone.0281150.PubMedUsed to support: Systematic review and meta-analysis of human trials confirming allulose (the compound in Sukré®) significantly attenuates postprandial blood glucose and reduces insulin response, directly supporting the blood glucose and insulin reduction claims.
  2. Han Y, Kwon EY, Yu MK, Lee SJ, Kim HJ, Kim SB, Kim YH, Choi MS A Preliminary Study for Evaluating the Dose-Dependent Effect of d-Allulose for Fat Mass Reduction in Adult Humans: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2018;10(2):160. doi: 10.3390/nu10020160.PubMedUsed to support: Double-blind, placebo-controlled RCT in adult humans demonstrating dose-dependent fat mass reduction with D-allulose supplementation, directly supporting the body fat reduction and anti-obesity claims for Sukré®.
  3. Braunstein CR, Noronha JC, Glenn AJ, Viguiliouk E, Noseworthy R, Khan TA, Au-Yeung F, Blanco Mejia S, Wolever TMS, Josse RG, Kendall CWC, Sievenpiper JL A Double-Blind, Randomized Controlled, Acute Feeding Equivalence Trial of Small, Catalytic Doses of Fructose and Allulose on Postprandial Blood Glucose Metabolism in Healthy Participants: The Fructose and Allulose Catalytic Effects (FACE) Trial. Nutrients. 2018;10(6):750. doi: 10.3390/nu10060750.PubMedUsed to support: Double-blind RCT demonstrating even catalytic (low) doses of allulose reduce postprandial blood glucose metabolism in healthy adults, supporting the blood glucose reduction claim for Sukré® (allulose) at practical serving sizes.
  4. Teysseire F, Bordier V, Budzinska A, Van Oudenhove L, Weltens N, Beglinger C, Wölnerhanssen BK, Meyer-Gerspach AC Metabolic Effects and Safety Aspects of Acute D-allulose and Erythritol Administration in Healthy Subjects. Nutrients. 2023;15(2):458. doi: 10.3390/nu15020458.PubMedUsed to support: Human acute crossover study confirming D-allulose (Sukré® compound) produces favorable glycemic and metabolic effects with good tolerability, supporting the zero-glycemic sweetening and insulin reduction claims and establishing a favorable safety profile.